Skip to content

Today's Technology For Tomorrow's Kidney Care

Kibow Pharma Clinical stage LBD Drug Company

In transition from Kidney health supplement to progress as a live biotherapeutic drug product development under CBER/USFDA. Submission of the Investigational New Drug(IND) application is in the process.

Intestinal Dialysis™ (a.k.a Enteric Dialysis®) – Modulating the Gut Microbiome with Probiotics and Prebiotics (Gut-Kidney Connection)

2020 Business of the Year

Delaware County Chamber of Commerce

Kibow Bio Awards Kidney Health

Bio - Biotechnology Innovation Organization

2005 - Innovation Corridor Abstract Winner, Boston, MA

2018 - Invited Company for Presentation, Boston, MA

Kibow Buzz of Bio Winner (Kidney Health)

2014 - Winner of “Buzz of Bio Awards”

The First dietary supplement Company to win this award. International Bio conference, San Diego, CA

Dun and Bradstreet Kibow Award

2019 - Dun & Bradstreet Award

In recognition of unwavering commitment to business growth

From www.theisn.org

SYMPOSIUM AT THE INTERNATIONAL SOCIETY OF ARTIFICIAL INTERNAL ORGANS IN EDINBURGH, SCOTLAND. Aug 04, 1999

850 million Adult

Worldwide 850 million adult are estimated to have Chronic Kidney Disease (CKD)

Risk Factors Include

Rick Factors for CKD includes diabetes, high blood pressure, heart disease, Obesity and Family history of Kidney problems

An estimated 1 in 10

An estimated 1 in 10 people worldwide have Chronic Kidney Disease (CKD)​

Utenim ad minim eniami quis nostrud exer.


Supported by Visionary & Distinguished Nephrologists and Scientists

SYMPOSIUM AT THE INTERNATIONAL SOCIETY OF ARTIFICIAL INTERNAL ORGANS IN EDINBURGH, SCOTLAND. Aug 04, 1999

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

Utenim ad minim eniami quis nostrud exer.

Testimonials

Kibow's Brands

News & Blog

Hello world!

Welcome to Kibow. This is your first

Hello world!

Welcome to simplifiyou Sites. This is your